Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05485987 · ClinicalTrials.gov registry record · Phase 2
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
A Phase 2 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05485987 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT05485987, a Phase 2 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
Interventions
- DRUG Vatiquinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05485987
The ClinicalTrials.gov registry entry for NCT05485987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vatiquinone is the first listed.
NCT05485987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05485987 about?
NCT05485987 is a clinical study titled "A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia". The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
What is the current status of trial NCT05485987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2022-10-12. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT05485987?
The interventions under investigation include: Vatiquinone (DRUG).
Who is sponsoring clinical trial NCT05485987?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.